Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | OT |
FBE calling to report AE for CAPVAXIVE on behalf HCP who is also the patient. Patient reports experiencing injection site pain immediately after receiving CAPVAXIVE. Patient reports the pain did not subside for a couple of days and still feels linger; This spontaneous report was received from a Consumer and refers to a Elderly female patient over 65 years of age. The patient's concurrent conditions/medical history included arthritis rheumatoid. Concomitant therapies, drug reactions or allergies were not provided. On an unspecified date in April 2025 (reported as "sometime in April"), the patient was vaccinated with a dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE), administered Intramuscularly (strength, lot #, expiration date, dose number, anatomical location not provided) as vaccination. The patient reported that immediately after receiving the vaccine, she experienced injection site pain, and the pain did not subside for a couple of days. On an unspecified date in 2025, the patient recovered from the event, but she stated that still felt lingering pain to this day. The causal relationship between vaccination site pain and Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was not reported.
Medical History/Concurrent Conditions: Rheumatoid arthritis